Muraglitazar
CAS No. 331741-94-7
Muraglitazar( —— )
Catalog No. M33747 CAS No. 331741-94-7
Muraglitazar (BMS-298585) is a PPAR α/γ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 683 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1416 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | 2558 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMuraglitazar
-
NoteResearch use only, not for human use.
-
Brief DescriptionMuraglitazar (BMS-298585) is a PPAR α/γ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia.
-
DescriptionMuraglitazar is a PPAR α/γ dual agonist for the research of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα (EC50 = 320 nM) and PPARγ(EC50 = 110 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetPPAR
-
RecptorPPAR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number331741-94-7
-
Formula Weight516.54
-
Molecular FormulaC29H28N2O7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(COC1=CC=C(CN(C(OC2=CC=C(OC)C=C2)=O)CC(O)=O)C=C1)C=3N=C(OC3C)C4=CC=CC=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005;27(8):1181-1195. ?
molnova catalog
related products
-
Pioglitazone
Pioglitazone is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.
-
Benzo[b]thiophene-7-...
Benzo[b]thiophene-7-propanoic acid, α-methoxy-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, (αR)- is a dual PPARα/γ agonist with EC50 of 0.358μM and 1.21μM.
-
SR 16832
SR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.
Cart
sales@molnova.com